US8715645B2
(en)
*
|
1994-05-27 |
2014-05-06 |
The Regents Of The University Of Colorado |
Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
|
US20050089958A1
(en)
*
|
1996-01-09 |
2005-04-28 |
Genentech, Inc. |
Apo-2 ligand
|
US6998116B1
(en)
*
|
1996-01-09 |
2006-02-14 |
Genentech, Inc. |
Apo-2 ligand
|
US6030945A
(en)
*
|
1996-01-09 |
2000-02-29 |
Genentech, Inc. |
Apo-2 ligand
|
US6046048A
(en)
*
|
1996-01-09 |
2000-04-04 |
Genetech, Inc. |
Apo-2 ligand
|
US20040038347A1
(en)
*
|
1996-03-14 |
2004-02-26 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule I
|
AU3381097A
(en)
*
|
1996-06-07 |
1998-01-05 |
Amgen, Inc. |
Tumor necrosis factor-related polypeptide
|
JP2002509431A
(ja)
*
|
1996-12-23 |
2002-03-26 |
イミュネックス・コーポレーション |
NF−κBのレセプター活性化因子−レセプターはTNFレセプタースーパーファミリーの一員である−
|
US7452538B2
(en)
*
|
1997-01-28 |
2008-11-18 |
Human Genome Sciences, Inc. |
Death domain containing receptor 4 antibodies and methods
|
US8329179B2
(en)
|
1997-01-28 |
2012-12-11 |
Human Genome Sciences, Inc. |
Death domain containing receptor 4 antibodies and methods
|
PT1012274E
(pt)
*
|
1997-01-28 |
2007-08-14 |
Craig A Rosen |
Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)
|
US6433147B1
(en)
|
1997-01-28 |
2002-08-13 |
Human Genome Sciences, Inc. |
Death domain containing receptor-4
|
US20020009467A1
(en)
|
1997-01-29 |
2002-01-24 |
Shozo Koyama |
Antigenic substance inductor, vaccine precursor, vaccine, antibody, neutralizing antibody, antitoxin, idiotype antibody and/or anti-idiotype antibody which is induced by its idiotype antibody
|
JP3813682B2
(ja)
*
|
1997-01-29 |
2006-08-23 |
小山 省三 |
ワクチン前駆体およびワクチン
|
WO1998035061A2
(fr)
*
|
1997-02-12 |
1998-08-13 |
Abbott Laboratories |
Element de la famille tnf utilise pour le traitement et le diagnostic d'une maladie
|
US7528239B1
(en)
|
1997-02-13 |
2009-05-05 |
Immunex Corporation |
Receptor that binds trail
|
US6072047A
(en)
|
1997-02-13 |
2000-06-06 |
Immunex Corporation |
Receptor that binds trail
|
US20010010924A1
(en)
*
|
1997-03-14 |
2001-08-02 |
Keith Charles Deen |
Tumor necrosis factor related receptor, tr6 polynecleotides
|
US20040136951A1
(en)
*
|
1997-03-17 |
2004-07-15 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
NZ508381A
(en)
*
|
1997-03-17 |
2002-09-27 |
Human Genome Sciences Inc |
Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
|
US20080248046A1
(en)
*
|
1997-03-17 |
2008-10-09 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
US6872568B1
(en)
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
US20050233958A1
(en)
*
|
1997-03-17 |
2005-10-20 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
US20020102706A1
(en)
*
|
1997-06-18 |
2002-08-01 |
Genentech, Inc. |
Apo-2DcR
|
US6316408B1
(en)
*
|
1997-04-16 |
2001-11-13 |
Amgen Inc. |
Methods of use for osetoprotegerin binding protein receptors
|
CZ302262B6
(cs)
|
1997-04-16 |
2011-01-19 |
Amgen Inc. |
Izolovaná nukleová kyselina, polypeptid kódovaný touto nukleovou kyselinou, expresní vektor obsahující tuto nukleovou kyselinu, hostitelská bunka transfekovaná tímto expresním vektorem, izolovaný protein vázající osteoprotegerin, protilátka vázající
|
US20100152426A1
(en)
*
|
1997-05-15 |
2010-06-17 |
Ashkenazi Avi J |
Apo-2 receptor fusion proteins
|
US6342369B1
(en)
*
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
DE69838249T3
(de)
*
|
1997-05-15 |
2012-01-19 |
Genentech, Inc. |
Anti-apo-2 antikörper
|
EP1032661A1
(fr)
*
|
1997-06-18 |
2000-09-06 |
Genentech, Inc. |
Apo-2DcR
|
US6171787B1
(en)
*
|
1997-06-26 |
2001-01-09 |
Abbott Laboratories |
Member of the TNF family useful for treatment and diagnosis of disease
|
WO1999002653A1
(fr)
*
|
1997-07-11 |
1999-01-21 |
Trustees Of The University Of Pennsylvania |
Acide nucleique codant une nouvelle proteine induite par chimiotherapie, et ses procedes d'utilisation
|
FR2766713B1
(fr)
*
|
1997-08-04 |
1999-09-24 |
Bio Merieux |
Facteur proteique associe a une maladie neuro-degenerative et/ou auto-immune et/ou inflammatoire
|
US6346388B1
(en)
|
1997-08-13 |
2002-02-12 |
Smithkline Beecham Corporation |
Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
|
EP1019508A1
(fr)
*
|
1997-09-30 |
2000-07-19 |
PHARMACIA & UPJOHN COMPANY |
Identification de ligand d'apoptose liee au tnf
|
JP4485049B2
(ja)
*
|
1997-11-18 |
2010-06-16 |
ジェネンテック, インコーポレイテッド |
Dna19355ポリペプチドという腫瘍壊死因子相同体
|
US7019119B2
(en)
*
|
1997-12-12 |
2006-03-28 |
The Rockefeller University |
Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
|
CA2318029C
(fr)
*
|
1998-01-15 |
2009-05-19 |
Genentech, Inc. |
Apo-2 ligand
|
US20040180049A1
(en)
*
|
1998-01-26 |
2004-09-16 |
Genentech, Inc. |
DR4 antibodies and uses thereof
|
US20040120947A1
(en)
*
|
1998-01-26 |
2004-06-24 |
Genentech, Inc. |
DR4 antibodies and uses thereof
|
NZ525914A
(en)
|
1998-03-10 |
2004-03-26 |
Genentech Inc |
Novel polypeptides and nucleic acids encoding the same
|
EP1941905A1
(fr)
|
1998-03-27 |
2008-07-09 |
Genentech, Inc. |
Synergie d'anticorps APO-2 ligand-anti-her-2
|
DE69938923D1
(de)
*
|
1998-03-27 |
2008-07-31 |
Genentech Inc |
Synergie zwischen apo-2 ligand und antikörper gegen her-2
|
JP2002517223A
(ja)
|
1998-06-12 |
2002-06-18 |
ジェネンテック・インコーポレーテッド |
モノクローナル抗体、交叉反応性抗体およびそれを生成する方法
|
IL140701A0
(en)
|
1998-07-13 |
2002-02-10 |
Univ Texas |
Cancer treatment methods using antibodies to aminophospholipids
|
WO2000026228A1
(fr)
*
|
1998-11-02 |
2000-05-11 |
Clontech Laboratories, Inc. |
Gene et proteine regulant la mort cellulaire
|
US20030187196A1
(en)
*
|
1998-12-30 |
2003-10-02 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20050281821A1
(en)
*
|
1999-01-06 |
2005-12-22 |
Flavia Pernasetti |
Method and composition for angiogenesis inhibition
|
US7696325B2
(en)
|
1999-03-10 |
2010-04-13 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide inducing apoptosis
|
ES2421720T3
(es)
|
1999-04-12 |
2013-09-05 |
Genentech Inc |
Homólogos del factor de necrosis tumoral y ácidos nucleicos que los codifican
|
WO2000063253A1
(fr)
*
|
1999-04-16 |
2000-10-26 |
Amgen Inc. |
Compositions de proteine hybride agp-1 et procedes connexes
|
EP1870464A3
(fr)
*
|
1999-06-02 |
2008-03-12 |
Genentech, Inc. |
Procédés et compositions d'inhibition de la croissance de cellules néoplasiques
|
CN100526463C
(zh)
*
|
1999-06-28 |
2009-08-12 |
杰南技术公司 |
利用二价金属离子制备Apo-2配体的方法
|
US6444640B1
(en)
*
|
1999-09-30 |
2002-09-03 |
Ludwig Institute For Cancer Research |
Compositions of trail and DNA damaging drugs and uses thereof
|
WO2001022987A1
(fr)
*
|
1999-09-30 |
2001-04-05 |
The Trustees Of The University Of Pennsylvania |
'trail' en tant qu'inhibiteur de l'inflammation auto-immune et de la progression du cycle cellulaire
|
CA2394015C
(fr)
|
1999-12-20 |
2013-11-05 |
Immunex Corporation |
Recepteur tweak
|
AU784614B2
(en)
*
|
2000-01-24 |
2006-05-11 |
University Of Louisville Research Foundation, Inc. |
Immune modulation with death receptor-induced apoptosis
|
US7927602B2
(en)
*
|
2002-07-23 |
2011-04-19 |
University Of Louisville Research Foundation, Inc. |
Fas ligand-avidin/streptavidin fusion proteins
|
IL150755A0
(en)
|
2000-02-16 |
2003-02-12 |
Genentech Inc |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
US20030103978A1
(en)
*
|
2000-02-23 |
2003-06-05 |
Amgen Inc. |
Selective binding agents of osteoprotegerin binding protein
|
KR20020093029A
(ko)
|
2000-04-11 |
2002-12-12 |
제넨테크, 인크. |
다가 항체 및 그의 용도
|
US6900185B1
(en)
|
2000-04-12 |
2005-05-31 |
University Of Iowa Research Foundation |
Method of inducing tumor cell apoptosis using trail/Apo-2 ligand gene transfer
|
CA2413237C
(fr)
|
2000-06-30 |
2013-09-10 |
University Of Louisville Research Foundation, Inc. |
Alteration des membranes cellulaires en vue d'obtenir de nouvelles fonctions
|
ATE415978T1
(de)
|
2000-07-27 |
2008-12-15 |
Genentech Inc |
Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
|
DE10045591A1
(de)
*
|
2000-09-15 |
2002-04-04 |
Klaus Pfizenmaier |
Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
|
RU2408606C2
(ru)
|
2000-10-20 |
2011-01-10 |
Тугаи Сейяку Кабусики Кайся |
Соединение - агонист тро
|
US20030228309A1
(en)
*
|
2000-11-08 |
2003-12-11 |
Theodora Salcedo |
Antibodies that immunospecifically bind to TRAIL receptors
|
US20060062786A1
(en)
*
|
2000-11-08 |
2006-03-23 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
EP1339426A4
(fr)
*
|
2000-11-08 |
2004-06-30 |
Human Genome Sciences Inc |
Anticorps a liaison immunospecifique avec les recepteurs "trail"
|
US20020155109A1
(en)
*
|
2001-04-20 |
2002-10-24 |
Lynch David H. |
Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
|
MXPA03010747A
(es)
|
2001-05-25 |
2004-03-02 |
Human Genome Sciences Inc |
Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
|
US20090226429A1
(en)
*
|
2001-05-25 |
2009-09-10 |
Human Genome Sciences, Inc. |
Antibodies That Immunospecifically Bind to TRAIL Receptors
|
US7348003B2
(en)
|
2001-05-25 |
2008-03-25 |
Human Genome Sciences, Inc. |
Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
|
US20050214209A1
(en)
*
|
2001-05-25 |
2005-09-29 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
US7361341B2
(en)
*
|
2001-05-25 |
2008-04-22 |
Human Genome Sciences, Inc. |
Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
|
US20050129616A1
(en)
*
|
2001-05-25 |
2005-06-16 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
GB0113920D0
(en)
|
2001-06-07 |
2001-08-01 |
Sterix Ltd |
Composition
|
MXPA04000134A
(es)
|
2001-06-26 |
2005-06-06 |
Abgenix Inc |
Anticuerpos para ligandos de osteoprotegerina.
|
ATE433996T1
(de)
|
2001-07-03 |
2009-07-15 |
Genentech Inc |
Humane dr4-antikörper und deren anwendungen
|
EP1420803A1
(fr)
*
|
2001-08-08 |
2004-05-26 |
Board Of Regents, The University Of Texas System |
Procede permettant d'amplifier l'expression a partir d'un promoteur a specificite cellulaire
|
WO2003029420A2
(fr)
*
|
2001-10-02 |
2003-04-10 |
Genentech, Inc. |
Variants de ligands apo-2 et leurs utilisations
|
US7842668B1
(en)
|
2001-11-13 |
2010-11-30 |
Genentech, Inc. |
Apo-2 ligand/trail formulations
|
AU2007200478A1
(en)
*
|
2001-11-13 |
2007-02-22 |
Genentech, Inc. |
APO2 ligand/trail formulations
|
US7741285B2
(en)
|
2001-11-13 |
2010-06-22 |
Genentech, Inc. |
APO-2 ligand/trail formulations
|
EP1450847B1
(fr)
*
|
2001-11-13 |
2010-09-29 |
Genentech, Inc. |
Compositions à base de APO2 ligand/TRAIL et leur utilisation
|
CN1610696A
(zh)
*
|
2001-12-20 |
2005-04-27 |
人体基因组科学有限公司 |
免疫特异性结合trail受体的抗体
|
AU2003220529B2
(en)
|
2002-03-27 |
2006-09-07 |
Immunex Corporation |
Methods for increasing polypeptide production
|
AU2003243139B2
(en)
*
|
2002-04-05 |
2007-06-21 |
Amgen Inc. |
Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
|
WO2004001009A2
(fr)
|
2002-06-24 |
2003-12-31 |
Genentech, Inc. |
Variants du ligand apo-2/trail et utilisations de ceux-ci
|
DK1537146T3
(da)
|
2002-07-15 |
2011-04-04 |
Univ Texas |
Antistoffer, der binder til anioniske phospholipider og aminophospholipider, og deres anvendelse til behandling af virusinfektioner
|
AU2003296310A1
(en)
*
|
2002-12-06 |
2004-06-30 |
University Of South Florida |
Histone deacetylase inhibitor enhancement of trail-induced apoptosis
|
JP2004279086A
(ja)
|
2003-03-13 |
2004-10-07 |
Konica Minolta Holdings Inc |
放射線画像変換パネル及び放射線画像変換パネルの製造方法
|
CN1852737A
(zh)
*
|
2003-09-18 |
2006-10-25 |
诺瓦提斯公司 |
组蛋白脱乙酰酶抑制剂与死亡受体配体的组合
|
AU2003280921B2
(en)
|
2003-11-03 |
2007-09-13 |
Beijing Sunbio Biotech Co., Ltd. |
A recombinant protein with cancer suppression action, its encoding gene and use
|
EP1710255A4
(fr)
|
2003-12-12 |
2008-09-24 |
Chugai Pharmaceutical Co Ltd |
Anticorps modifies reconnaissant un recepteur trimere ou plus grand
|
DK1718283T3
(da)
|
2004-01-22 |
2013-04-22 |
Univ Miami |
Topisk co-enzyme Q10 formuleringer og fremgangsmåder for anvendelse.
|
WO2005082934A2
(fr)
*
|
2004-02-20 |
2005-09-09 |
Five Prime Therapeutics, Inc. |
Nouveaux polypeptides apo2l et il-24, polynucleotides, et leurs procedes d'utilisation
|
SI1733037T1
(sl)
|
2004-03-11 |
2015-02-27 |
Genentech, Inc. |
Postopek za izdelavo polipeptidov
|
EP1756162A1
(fr)
|
2004-03-23 |
2007-02-28 |
Biogen Idec MA Inc. |
Agents de couplage recepteurs et leurs applications therapeutiques
|
MX2007001469A
(es)
|
2004-08-06 |
2007-03-26 |
Genentech Inc |
Ensayos y metodos que utilizan biomarcadores.
|
JP5140421B2
(ja)
*
|
2004-08-06 |
2013-02-06 |
ジェネンテック, インコーポレイテッド |
バイオマーカーを用いたアッセイおよび方法
|
KR20070050951A
(ko)
*
|
2004-09-08 |
2007-05-16 |
제넨테크, 인크. |
사멸 수용체 리간드 및 cd20 항체의 사용 방법
|
WO2006029224A2
(fr)
*
|
2004-09-08 |
2006-03-16 |
Genentech, Inc. |
Procedes d'utilisation de ligands des recepteurs de mort et d'anticorps cd20
|
EP1645875A1
(fr)
*
|
2004-10-08 |
2006-04-12 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Diagnostic et thérapie de cellules cancéreuses à partir de la résistance à l'apoptose conférée par TRAIL
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
US20060228352A1
(en)
*
|
2005-02-24 |
2006-10-12 |
Schoenberger Stephen P |
TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
|
JP2006265155A
(ja)
*
|
2005-03-23 |
2006-10-05 |
Link Genomics Kk |
癌の免疫療法
|
US9493569B2
(en)
|
2005-03-31 |
2016-11-15 |
Chugai Seiyaku Kabushiki Kaisha |
Structural isomers of sc(Fv)2
|
CA2610987C
(fr)
|
2005-06-10 |
2013-09-10 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilisant pour une preparation de proteine contenant de la meglumine et son utilisation
|
CN101262885B
(zh)
|
2005-06-10 |
2015-04-01 |
中外制药株式会社 |
含有sc(Fv)2的药物组合物
|
CA2619759A1
(fr)
|
2005-08-16 |
2007-02-22 |
Genentech, Inc. |
Sensibilite de l'apoptose au trail ap02l par controle de l'expression genetique galnac t14 dans des cellules ou des tissus
|
EP1928497A2
(fr)
*
|
2005-08-24 |
2008-06-11 |
Cell-Matrix, Inc. |
Therapies combinees visant a inhiber les interactions integrine-matrice extracellulaire
|
PE20071101A1
(es)
*
|
2005-08-31 |
2007-12-21 |
Amgen Inc |
Polipeptidos y anticuerpos
|
AU2006318539B2
(en)
|
2005-11-23 |
2012-09-13 |
Genentech, Inc. |
Methods and compositions related to B cell assays
|
GB0524316D0
(en)
*
|
2005-11-29 |
2006-01-04 |
Medical Res Council |
Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
|
WO2008008155A2
(fr)
*
|
2006-06-20 |
2008-01-17 |
The Trustees Of The University Of Pennsylvania |
Modulateurs à petites cellules du signalement de la famille p53
|
US8008261B2
(en)
|
2006-08-04 |
2011-08-30 |
Mayo Foundation For Medical Education And Research |
Methods of reducing trail-induced apoptosis by trail isoforms
|
EP2136831B1
(fr)
|
2007-03-02 |
2012-09-12 |
The Cleveland Clinic Foundation |
Peptides anti-angiogéniques
|
AU2013203061B2
(en)
*
|
2007-07-10 |
2016-07-28 |
Apogenix Ag |
TNF superfamily collectin fusion proteins
|
ES2560871T3
(es)
|
2007-07-10 |
2016-02-23 |
Apogenix Gmbh |
Proteínas de fusión de colectina de la superfamilia de TNF
|
WO2009025743A2
(fr)
*
|
2007-08-17 |
2009-02-26 |
University Of Massachusetts Medical School |
Utilisation de compositions trail en tant qu'agents antiviraux
|
CN101157729B
(zh)
*
|
2007-10-23 |
2011-01-12 |
南京大学 |
一种肿瘤坏死因子相关凋亡配体变体及其应用
|
MX2010005104A
(es)
|
2007-11-09 |
2010-08-04 |
Peregrine Pharmaceuticals Inc |
Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
|
EA201190025A1
(ru)
|
2008-11-25 |
2012-12-28 |
Байоджен Айдек Ма Инк. |
ПРИМЕНЕНИЕ АНТАГОНИСТОВ DR6 И p75 ДЛЯ ПРОМОТИРОВАНИЯ ВЫЖИВАНИЯ КЛЕТОК НЕРВНОЙ СИСТЕМЫ
|
ES2593049T3
(es)
|
2009-01-09 |
2016-12-05 |
Apogenix Ag |
Proteínas de fusión que forman trímeros
|
US20100316639A1
(en)
|
2009-06-16 |
2010-12-16 |
Genentech, Inc. |
Biomarkers for igf-1r inhibitor therapy
|
ES2356880B8
(es)
|
2009-08-21 |
2012-10-30 |
Universidad De Zaragoza |
Liposomas recubiertos con el dominio extracelular de la proteína apo2l/trail.
|
JP2013507124A
(ja)
*
|
2009-10-09 |
2013-03-04 |
アナフォア インコーポレイテッド |
Il−23rを結合するポリペプチド
|
EP2556840B1
(fr)
*
|
2010-04-01 |
2017-09-27 |
Korea Research Institute of Bioscience and Biotechnology |
Composition pour l'augmentation de la sensibilité de trail contenant un inhibiteur pour l'inhibition de l'expression ou de l'activité de tip41 qui est un gène cible sensibilisateur de trail
|
PL391627A1
(pl)
*
|
2010-06-25 |
2012-01-02 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Przeciwnowotworowe białko fuzyjne
|
WO2012019160A1
(fr)
|
2010-08-05 |
2012-02-09 |
Amgen Inc. |
Dipeptides pour améliorer le rendement et la viabilité de cultures cellulaires
|
CA2814595C
(fr)
|
2010-12-03 |
2020-06-16 |
Adamed Sp. Z O.O. |
Proteine de fusion anticancereuse
|
PL219845B1
(pl)
|
2011-01-05 |
2015-07-31 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Przeciwnowotworowe białko fuzyjne
|
PL394618A1
(pl)
|
2011-04-19 |
2012-10-22 |
Adamed Spólka Z Ograniczona Odpowiedzialnoscia |
Przeciwnowotworowe bialko fuzyjne
|
WO2012145682A1
(fr)
|
2011-04-21 |
2012-10-26 |
Amgen Inc. |
Méthode de culture de cellules de mammifère pour améliorer la production de protéines recombinantes
|
CA2834776A1
(fr)
|
2011-05-03 |
2012-11-08 |
Genentech, Inc. |
Agents d'interruption vasculaire et utilisations associees
|
CN103827292B
(zh)
|
2011-07-01 |
2018-01-26 |
安姆根有限公司 |
哺乳动物细胞培养
|
CN102908612A
(zh)
*
|
2011-08-02 |
2013-02-06 |
北京诺赛基因组研究中心有限公司 |
TRAIL截短型变异体活化NF-κB和在炎症反应中的应用
|
CA2840637A1
(fr)
|
2011-09-02 |
2013-03-07 |
Amgen Inc. |
Produit pharmaceutique et procede d'analyse de l'exposition lumineuse d'un produit pharmaceutique
|
CN103534273B
(zh)
*
|
2011-09-16 |
2020-05-12 |
北京沙东生物技术有限公司 |
环化变构trail/apo2l及其编码基因与应用
|
PL397167A1
(pl)
|
2011-11-28 |
2013-06-10 |
Adamed Spólka Z Ograniczona Odpowiedzialnoscia |
Przeciwnowotworowe bialko fuzyjne
|
AR089231A1
(es)
|
2011-12-15 |
2014-08-06 |
Amgen Inc |
Metodo de floculacion
|
PL223487B1
(pl)
|
2011-12-28 |
2016-10-31 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Przeciwnowotworowe białko fuzyjne
|
EP2931287B1
(fr)
*
|
2012-12-11 |
2017-10-04 |
Sapiotec GmbH |
Delphinidin contre les cellules de mélanome
|
WO2014109858A1
(fr)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Méthodes d'utilisation d'inhibiteurs de cycle cellulaire pour moduler une ou plusieurs propriétés d'une culture cellulaire
|
US10023608B1
(en)
|
2013-03-13 |
2018-07-17 |
Amgen Inc. |
Protein purification methods to remove impurities
|
TWI832345B
(zh)
|
2013-03-14 |
2024-02-11 |
美商安美基公司 |
用於增加重組蛋白質之甘露糖含量之方法
|
SI2969099T2
(sl)
|
2013-03-14 |
2022-04-29 |
Amgen Inc. |
Odstranjevanje izluženega afinitetnega purifikacijskega liganda
|
WO2014159562A1
(fr)
|
2013-03-14 |
2014-10-02 |
Bristol-Myers Squibb Company |
Combinaison d'agoniste de dr5 et d'antagoniste anti-pd-1 et méthodes d'utilisation associées
|
US9481901B2
(en)
|
2013-05-30 |
2016-11-01 |
Amgen Inc. |
Methods for increasing mannose content of recombinant proteins
|
EA036275B1
(ru)
|
2013-06-25 |
2020-10-21 |
Дзе Уолтер Энд Элиза Хол Инститьют Оф Медикал Рисерч |
Способ лечения внутриклеточной инфекции
|
CN103555729B
(zh)
*
|
2013-10-14 |
2016-08-24 |
成都华创生物技术有限公司 |
一种改造的trail基因序列、表达方法及应用
|
EP3063287A1
(fr)
|
2013-10-31 |
2016-09-07 |
Amgen Inc. |
Utilisation de monensine pour réguler la glycosylation de protéines de recombinaison
|
EP3094735A1
(fr)
|
2014-01-13 |
2016-11-23 |
Amgen Inc. |
Régulation du métabolisme de l'ornithine pour manipuler la teneur en glycoformes à haute teneur en mannose de protéines de recombinaison
|
KR102519540B1
(ko)
|
2014-01-29 |
2023-04-10 |
암젠 인크 |
재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현
|
US10106829B2
(en)
|
2014-01-29 |
2018-10-23 |
Amgen Inc. |
Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
WO2015138638A1
(fr)
|
2014-03-11 |
2015-09-17 |
Theraly Pharmaceuticals, Inc. |
Agonistes de récepteur de protéine trail à action prolongée pour le traitement de maladies auto-immunes
|
PL3152317T3
(pl)
|
2014-06-04 |
2019-08-30 |
Amgen Inc. |
Sposoby zbierania hodowli ssaczych komórek
|
US11275090B2
(en)
|
2014-11-19 |
2022-03-15 |
Amgen Inc. |
Quantitation of glycan moiety in recombinant glycoproteins
|
CA2969225C
(fr)
|
2014-12-01 |
2023-08-22 |
Amgen Inc. |
Procede de manipulation du taux de contenu de glycane d'une glycoproteine
|
US11279768B1
(en)
|
2015-04-03 |
2022-03-22 |
Precision Biologics, Inc. |
Anti-cancer antibodies, combination therapies, and uses thereof
|
CN108601819B
(zh)
|
2015-12-17 |
2022-03-15 |
约翰霍普金斯大学 |
用死亡受体激动剂改善系统性硬化症
|
CA3007419A1
(fr)
|
2015-12-30 |
2017-07-06 |
Genentech, Inc. |
Formulations presentant une moindre degradation des polysorbates
|
CN116064677A
(zh)
*
|
2016-02-05 |
2023-05-05 |
斯比根公司 |
表达trail和cd的间充质干细胞及其用途
|
JP7281795B2
(ja)
|
2016-04-07 |
2023-05-26 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法
|
KR101739703B1
(ko)
*
|
2016-09-13 |
2017-05-24 |
(주) 어드밴스드 엔티 |
Trail 기반 뇌염 감별진단 방법 및 장치
|
CA3099163A1
(fr)
|
2018-05-01 |
2019-11-07 |
Amgen Inc. |
Anticorps presentant des profils de glycane modules
|
US11519007B2
(en)
|
2019-02-22 |
2022-12-06 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Tumor-navigating, self-eradicating, trail-armed salmonella for precision cancer therapy
|
KR20240128067A
(ko)
|
2021-12-29 |
2024-08-23 |
브리스톨-마이어스 스큅 컴퍼니 |
랜딩 패드 세포주의 생성
|